Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02046187 |
|
Recruitment Status :
Terminated
(excessive protocol deviations due to strict nature of diet requirements)
First Posted : January 27, 2014
Last Update Posted : June 16, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study aims to see if reducing blood sugar and increasing ketones (a metabolic product that comes from using fats for energy) can increase survival and enhance the the effects of standard radiation and chemotherapy treatments used to treat glioblastoma multiforme (GBM). These changes occur from use of a ketogenic diet. This research has 2 goals:
- Show that patients can tolerate the diet and maintain low blood glucose and high blood ketone levels.
- Show if this diet enhances the effectiveness of standard treatment by prolonging survival of patients with a GBM.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Glioblastoma (GBM) | Dietary Supplement: Ketogenic Diet Radiation: Radiation therapy Drug: Temozolomide | Phase 1 Phase 2 |
The investigators propose to offer this study to patients with newly diagnosed glioblastoma multiforme (GBM) that undergo gross total resection (GTR) or subtotal resection (STR) of their tumor. Post-operatively, these patients and their families will be instructed in the implementation of the Ketogenic Diet (KD) and it will be started as soon as possible following surgery to achieve ketosis and reduction of blood sugar. Patients will receive standard chemoradiotherapy with fractionated external beam radiation (60Gy) and concurrent oral temozolomide chemotherapy followed by 12 adjuvant cycles of temozolomide chemotherapy on a standard dose schedule. Outcome measures of the study group will be compared to historic controls in the treatment arm from the European Organization for Research and Treatment of Cancer (EORTC) temozolomide study published by Roger Stupp et al, New England Journal of Medicine, March 10, 2005.
Note: Gross Total Resection (GTR), Subtotal Resection (STR), temozolomide (Temodar), and radiation therapy are routine care for GBM and are not an investigational component of this study.
Study end-points:
Primary: Ketogenic diet (KD) tolerance and compliance in brain tumor patients. The diet will be considered tolerable if the patient chooses to remain compliant. Compliance is monitored by the dietician using self reporting of diet, blood glucose and blood ketone levels.
Secondary: Overall survival, time to recurrence, health and therapy-related quality of life. Overall survival and progression free survival will be measured and compared to the historic controls who received chemoradiotherapy in standard dose scheduling.
Laboratory correlate: Molecular/immunohistochemical analysis of tumors that do and do not respond to a KD.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 14 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase I/II Prospective Trial for Newly Diagnosed GBM, With Upfront Gross or Subtotal Resection, Followed by Ketogenic Diet With Radiotherapy and Concurrent Temodar(R) Chemotherapy Followed by Adjuvant Temodar(R) Chemotherapy. |
| Actual Study Start Date : | October 2013 |
| Actual Primary Completion Date : | February 2017 |
| Actual Study Completion Date : | February 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Ketogenic Diet
Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
|
Dietary Supplement: Ketogenic Diet
Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis. Radiation: Radiation therapy Patients receive standard dose (60Gy/30 fractions) external beam radiation Drug: Temozolomide patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
Other Names:
|
- Number of participants with adverse events [ Time Frame: 8 weeks ]Number of participants with adverse events from initiation of ketogenic diet through end of radiation (while on ketogenic diet)
- overall survival [ Time Frame: 2 years ]overall survival
- time to progression [ Time Frame: 2 years ]time to progression
- quality of life [ Time Frame: 2 years ]patient reported outcome of their quality of life using FACT-BR (version 4) survey
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- adult patients, 18 - 80 years of age,
- a single enhancing lesion of the brain with MRI appearance consistent with GBM
- Pathologic confirmation of GBM
- Zubrod Performance Scale (ZPS) < 2
- Must be able to undergo MRI imaging with gadolinium
- Must have access to a computer and the internet (to use KetoCalculator© on-line Database)
Exclusion Criteria:
- unable to undergo MRI with gadolinium
- genetic disorders of fat metabolism
- patients receiving sodium valproate (may cause false ketone reading in urine)
- diabetes
- enrolled in another treatment trial for GBM
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02046187
| United States, Arizona | |
| Barrow Neurological Institute at St. Joseph's Hospital and Medical Center | |
| Phoenix, Arizona, United States, 85013 | |
| Study Chair: | Adrienne C Scheck, PhD | Barrow Neurological Research |
| Responsible Party: | St. Joseph's Hospital and Medical Center, Phoenix |
| ClinicalTrials.gov Identifier: | NCT02046187 |
| Other Study ID Numbers: |
KD-13BN069 |
| First Posted: | January 27, 2014 Key Record Dates |
| Last Update Posted: | June 16, 2021 |
| Last Verified: | June 2021 |
|
Ketogenic Diet Brain tumor Glioma Glioblastoma |
Radiation Chemotherapy temozolomide |
|
Glioblastoma Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Temozolomide Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |